Euroopa Liit - eesti - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosupressandid - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosupressandid - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - soliris on näidatud täiskasvanute ja laste raviks:paroxysmal öise haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5. ebatüüpiline hemolüütilis-ureemilise sündroomi (ahus). soliris on näidustatud täiskasvanute raviks:tulekindlad generaliseerunud myasthenia gravis (gmg) patsientidel, kes on anti-atsetüülkoliin retseptori (achr) antikeha-positiivsete (vt lõik 5. neuromyelitis optica spectrum disorder (nmosd) patsientidel, kes on anti-aquaporin-4 (aqp4) antikeha-positiivsete koos relapsing haiguse kulg.

Euroopa Liit - eesti - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Eesti - eesti - Ravimiamet

virbac - tseftiofuur+ketoprofeen - süstesuspensioon - 50mg+150mg 1ml 50ml 1tk; 50mg+150mg 1ml 250ml 1tk; 50mg+150mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

norbrook laboratories (ireland) limited - tseftiofuur - süstesuspensioon - 50mg 1ml 100ml 1tk; 50mg 1ml 250ml 1tk; 50mg 1ml 50ml 1tk

Eesti - eesti - Ravimiamet

wirtschaftsgenossenschaft deutscher tieraerzte eg - tsefkvinoom - süstesuspensioon - 25mg 1ml 250ml 1tk; 25mg 1ml 250ml 6tk; 25mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

interchemie werken de adelaar eesti aktsiaselts - tsefkvinoom - süstesuspensioon - 25mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

bimeda animal health limited - tsefapiriin - intrauteriinsuspensioon - 500mg 19g 19g 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - tsefuroksiim - õhukese polümeerikattega tablett - 500mg 6tk; 500mg 10tk; 500mg 14tk; 500mg 50tk; 500mg 24tk; 500mg 12tk; 500mg 16tk; 500mg 20tk